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Background: In non-small cell lung cancer patients (NSCLC), median survival from the time patients develop bone
metastasis is classically described being inferior to 6 months. We investigated the subcategory of patients having an
inaugural skeletal-related-event revealing NSCLC. The purpose of this study was to assess the impact of bone
involvement on overall survival and to determine biological and tumoral prognosis factors on OS and PFS. An
analysis of the subgroup of solitary bone metastasis patients was also performed.
Methods: In a population of 1208 lung cancer patients, 55 consecutive NSCLC patients revealed by inaugural
bone metastasis and treated between 2003 and 2010, were retrospectively analysed. Survival was measured with
a Kaplan-Meyer curve. Univariate and multivariate analysis were performed using the Stepwise Cox proportional
hazard regression model. A p value of less than 0,05 was considered statistically significant.
Results: Estimated incidence of revealing bone metastasis is 4,5% among newly diagnosed lung cancer
patients. Median duration of skeletal symptoms before diagnosis was 3 months and revealing bone site was
located on axial skeleton in 70% of the cases. Histology was adenocarcinoma (78%), with small primary tumors
Tx-T1-2 accounting for 71% of patients. Rate of second SRE is 37%.
Median overall survival was 8.15 months, IQR [5–16 months], mean survival 13.4 months, and PFS was 3.5 months.
In multivariate analysis, variables significantly associated with shortened survival were advanced T stage (HR = 2.8;
p = 0.004), weight loss > 10% (HR = 3.1; p = 0.02), inaugural spinal epidural metastasis (HR 2.5; p = 0.0036), elevated
C-reactive protein (HR = 4.3; p = 0.002) and TTF-1 status (HR = 2.42; p = 0.004). Inaugural spinal epidural metastasis
is a very strong adverse pronostic factor in these cases, with a 3 months median survival. Single bone metastasis
patients showed prolonged survival of 14.2 months versus 7.6 months, only in univariate analysis (HR = 0.42; p = 0.0059).
Conclusion: Prognosis of lung cancer patients with inaugural SRE remains pejorative. Accurately estimating the
survival of this population is helpful for bone surgical decision-making at diagnosis. The trend for a higher proportion of
adenocarcinoma in NSCLC patients should result with an increasing number of patients with inaugural SRE at diagnosis.
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Metastatic lung cancer accounts for approximately 58%
of newly diagnosed lung cancer as described by a large
french prospective epidemiological study conducted in
2010 [1].
It has been estimated that 30% to 65% of patients with
metastatic lung cancer will develop bone metastases [2]* Correspondence: melanie.deberne@curie.fr
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reproduction in any medium, provided the orand median survival from the time patients develop
bone metastasis is classically considered as less than
6 months [3].
However, with the introduction of new therapeutic
agents such as antiangiogenic therapies or EGFR inhibitors,
especially in adenocarcinoma, median survival for patients
with advanced stages has increased from approximately
6 months to 12 months [4] thereby extending their dis-
ease course and potentially increasing the risk of sub-
sequent skeletal-related-events (SREs). SREs are definedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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quirement for radiation or surgery to the bone, and malig-
nant hypercalcemia, leading to significant morbidities or
are associated with shortened survival.
Few data are available regarding the prognosis of pa-
tients having an inaugural SRE in non small cell lung
cancer (NSCLC). Sugiura et al. reported a median sur-
vival of 7.2 months from the time patients develop bone
metastasis in the disease course [5] and a recent study
by Bae et al., assessing pronostic factors for 196 non-
small cell lung cancer with bone metastasis at the time
of diagnosis, showed that ECOG performans status 0–
1 and single metastasis were associated with prolonged
survival for these patients with synchronous bone
metastasis [6].
Lung cancer patients presenting a SRE at diagnosis are
challenging, and require a multidisciplinary therapeutic
approach, both systemic and local, on the bone disease.
Accurately estimating the survival of these population is
also helpful for surgical decision-making [7,8].
In this study, we retrospectively analysed 55 NSCLC
patients revealed by an inaugural SRE. Our first object-
ive was to investigate the influence of bone metastatic
involvement on overall survival. Secondary aims were
to report epidemiologic characteristics of this popula-
tion and to assess clinical and biological prognosis
factors of survival and progression-free-survival. We
also performed an analysis of patients with single bone
metastasis.Table 1 Patients characteristics
Characteristics n = 55
Gender (Male/Female) 65.5%/ 34.5%
Age (yr, mean) 62.5
Histology
Adenocarcinoma 78.2%
Squamous cell carcinoma 3.6%






N0-1/ N2/ N3 56.5%/30.4%/13.1%Methods
Study population
From our department databases, we identified 55 patients
with NSCLC revealed by inaugural bone metastasis who
were treated between March 2003 and January 2009 at the
Oncology Department of Cochin Hospital (Paris) and
Institut Curie (Paris). The last follow-up evaluation was
performed in January 2012. At the time of final survival
analysis, two patients were alive.
Median follow-up is 8.3 months and survival interquar-
tile range (IQR) is [5–16 months].
Variables considered for analysis were: patients demo-
graphics, smoking history, weight loss, duration of bone
symptoms at diagnosis and OMS status, TNM according
to UICC 1997, TTF-1 status, presence and sites of vis-
ceral involvement and treatment schedule (chemotherapy,
biphosphonates).
Bone disease characteristics were assessed with total
number and sites of bone metastasis, location of revealing
bone lesion and predominant symptom revealing the le-
sion (defined as pain, neurologic symptom, hypercalcemia,
fracture, or spinal epidural metastasis (SEM), as well as
occurrence of a second SRE.Ethics approval
This retrospective study has received the approval of the
ethic comittee of Paris Descartes University, France, and
been carried out in compliance with the guidelines of
the Helsinki Declaration of 1975. Clinical informations
were anonymized for statistical work-up.
Statistical analysis
The primary outcome of the study was to investigate the
impact of the bone metastatic disease on overall survival
and PFS. Survival and disease control from the beginning
of the treatment to the date of last follow-up or event
were measured with a Kaplan-Meyer curve. Statistical
differences between curves were calculated by using the
log-rank test for the putative prognostic factors. Com-
parisons between groups were made using the Pearson
or maximum-likelihood test for categorical data and the
Student t test for comparison of means. Univariate and
multivariate analysis were performed using the stepwise
Cox proportional hazard regression model. A p value of
less than 0,05 was considered statistically significant.
Results
Incidence of bone metastasis revealing lung cancer and
patient characteristics
On 349 NSCLC patients treated at Cochin Hospital
during this period, 27% (94) patients had synchronous
or metachronous bone involvement, and 12% (42) had
bone metastasis as first manifestation of their lung
cancer. At Institut Curie, the estimated rate of bone
metastasis revealing NSCLC is 2% on 859 patients.
Baseline characteristics of patients are shown in Table 1.
Median age was 62.5 years at diagnosis – with a range of
31 to 92 years. The histologic subtype of NSCLC was
adenocarcinoma (78%), squamous cell carcinoma (3.6%)
and large cell carcinoma (18.2%).
Figure 1 Overall survival according to Kaplan-Meyer.
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nosis is 5 months. Thirty-six patients- 65.5%- had multiple
skeletal lesions and nineteen patients −34.5%- one bone
lesion, independently of the visceral metastatic status.
Twenty-five patients - 45.5% - had exclusive bone dis-
semination without visceral disease; among them ten
patients -18%- presented a single bone lesion.
Revealing bone site was located on axial skeleton in
70% of cases: vertebra in 34.5%, pelvis in 34.5%, while
extra-axial metastasis involved scapula (16.4%), long bone
like humerus or femur (16.4%) and ribs (3.6%). Among
spine localizations, thoracic level is the first revealing site
(63%), followed by lumbar level (33%); only one patient
suffered from a C7 lesion accompanied by a C7-D1
cervico-brachial neuralgia. Revealing symptoms were:
bone pain (78%), spinal epidural metastasis or cord
compression (14.5%) and pathologic fracture (7.2%).
No symptomatic malignant hypercalcemia was ob-
served, but biological hypercalcemia was noted in 22%
of cases. Therapeutic features are described in Table 2.
Analysis of predictive risk factors for overall survival,
progression-free-survival and skeletal-related-events
Median survival obtained by the non parametric method
of Kaplan and Meyer was 8.15 months, and mean
survival 13.4 months (Figure 1). Survival interquartile
range is IQR [5–16 months]. The actuarial 6 months, 1
and 2-year survival rates are respectively 69%, 32% and
9%. Presence of revealing bone site located in spine
(HR = 1.72; p = 0.054) and spinal epidural metastasis
(HR = 2.4; p = 0.017) were significantly associated with a
decreased survival in univariate analysis.
Univariate survival analysis showed as highly significant
prognostic factors for longer survival the following pretreat-
ment characteristics (Table 3): Performans status 0–1
(HR = 2.1; p = 0.007), weight loss less than 10% (HR 2.58;
p = 0.002), positive TTF-1 status (HR = 0.54; p = 0.03), early
stage T0-T1 versus T2-3-4 (HR = 2.37; p = 0.0013), and
absence of visceral involvement (HR = 1.8; p = 0.025). The
subgroup of patients with no visceral metastasis had aTable 2 Bone disease management and systemic
treatment
Therapeutic on first SRE n - %
Radiotherapy 38 - 70.4%
Surgery followed by radiotherapy 9 - 14.8%
Percutaneous vertebroplasty/Medical treatments 2/6 - 14.8%
Biphosphonates 33 - 60%
Systemic treatment
First line chemotherapy 53 - 96%
Second line chemotherapy 31 - 56%median survival of 12.6 months versus 6.45 months (HR =
1.8; CI 1-3.13; p = 0.025).
The number of bone metastases, independent of visceral
involvement status, does not reach significativity for
survival in univariate analysis: the group of 19 patients
with one bone lesion experienced a median survival of
9.7 months versus 7.6 months for those with multiple
skeletal lesions (p =0.11). Therefore, the subgroup of 10
patients having a single bone metastasis without visceral
disease has a significantly more favourable median survival
of 14.2 months versus 7.6 months for the rest of the popu-
lation (HR = 0.42; CI95% 0.23-0.73; p = 0.0059).
Pretherapeutic biological parameters associated with
increased survival are listed in Table 4.
Finally, in multivariate analysis (Table 5), variables
significantly associated with decreased overall survival
were T stage (HR = 2.8; p = 0.004), weight loss more
than 10% (HR = 3.1; p = 0.02), inaugural spinal epidural
metastasis (HR 2.5; p = 0.0036), elevated C-reactive
protein (HR = 4.3; p = 0.002) and negative TTF-1 status
( HR = 2.42; p = 0.004).
We also analysed the prognostic factors associated
with systemic progression-free-survival under first line
chemotherapy- all types of progression (skeletal or visceral)
were recorded. Median PFS for the entire population is
3.5 months.
In univariate analysis, the same variables found to be
pronostic for overall survival were discriminant for
progression-free-survival such as T stage (HR = 2.16, CI95%
1.16-4; p = 0.0042), TTF-1 status (HR =0.41, CI95%
0.21-0.8; p = 0.04) and performans status (HR =2.06, CI95%
1.1-3.8; p = 0.006), albuminemia ≥35 g/L (HR = 0.41,
CI95% 0.15-1.13; p = 0.014), and a C-Reactive Protein
under 7 mg/L (HR = 2.66, CI95% 1.47-4.8; p = 0.001).
In multivariate analysis, the only clinical parameter
found to be prognostic for PFS is the presence of vis-
ceral metastasis (HR = 2.8, CI95% 1.44-5.7; p = 0.0029),
Table 3 Univariate analysis of clinical and histological parameters on overall survival
Tumoral and patients characteristics N OS (months) HR p
OMS 0-1 32 12 2.10 0.007
Vs 2-3 21 6.2 CI 95% 1.11-3.9
Weight loss≥ 10% 12 3.4 2.58 0.002
< 10% 41 11 CI 95% 1.06-6
Adenocarcinoma 43 8.3 0.93 0.84 - NS
Vs others histological subtypes 12 7.8 CI 95% 0.49- 1.8
TTF1 negative 22 6.4 0.54 0.03
Vs positive 28 15.4 CI 95% 0.29- 1
T0-1 26 15.5 2.37 0.0013
vs T2-3-4 23 6.6 CI 95% 1.25-4.4
No visceral involvement 25 12.6 1.8 0.025
Vs visceral involvement 30 6.4 CI 95% 1–3.13
Solitary bone metastasis 10 14.2 0.42 0.0059
Vs multiple bone and/or visceral metastasis 45 7.6 CI 95% 0.23-0.73
Revealing site: spine 19 6,3 1.72 0.054
vs other sites 36 10 CI 95% 0.90-3.27
Spinal epidural metastasis
Yes 9 3 2.4 0.017
No 46 9,7 CI 95% 0.83-5.95
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6.2 months.
Second skeletal-related event: rate and description
The occurrence rate of second SRE is 37% (20 patients/55),
arising in a median delay of 3.7 months.
The repartition of second SRE was: radiation therapy
for analgesic purpose (11 pts), spinal chord compression
(7) with paraplegia, one fracture, one malignant hyper-
calcemia. Therapeutic on this second SRE was radiation
therapy in 60% cases, surgery for two patients, and
medical treatments for the 30% others. Two patients
who had been irradiated for a C7 and T7 instable ver-
tebral involvement underwent surgery by laminectomy
in a delay of 30 days after radiotherapy, due to neuro-
logic dysfunction.
No characteristic of the initial bone disease could be
correlated with the risk of occurrence of second SRE (i.e.
axial versus peripheral involvement, number of bone le-
sions or administration of biphosphonates). Baseline high
rate of alcaline phosphatasis was significant for a shorter
survival (p = 0,016) in univariate analysis, but was not
predictive for the occurrence of a second SRE.
In this limited serie, biphosphonates did not seem to
impact the occurrence of second SRE, since 43% of the
patients who received biphosphonates had experienced a
second SRE versus 31% in the group without bipho-
sphonates, all these data being non-significant. This factmainly reflects the under-prescription of biphosphonates
before 2008.
Subgroup analysis of patients with single bone
metastasis
The subgroup of 10 patients having a single bone me-
tastasis without visceral involvement has a significantly
more favourable median survival of 14.2 months versus
7.6 months for the rest of the population (HR = 0.42;
CI95% 0.23-0.73; p = 0.0059). This subgroup presents
also a prolonged median time to progression of 6.8 months
versus 3.5 months ( HR = 0.54, CI95% 0.3-0.96; p = 0.0443).
Their frequency of second skeletal event is 58%, probably
due to their prolonged survival. Eighty percent of these
single bone metastasis are located on pelvis, scapular belt,
long bone or thoracic chest, demonstrating that vertebral
involvement is more often linked with a polymetastatic
disease. On ten patients, eight had a biopsy-proven hist-
ology on the bone.
Repartition and treatment of these solitary skeletal
metastasis were as follow:
– Metastasis on the humeral glene ( 1 pt), treated by
resection, full humeral prosthesis and adjuvant
radiotherapy 30 Gy/10 fr.
– Metastasis of the coxo-femoral articulation or
femoral bone (2pts), treated by total hip replacement








Table 4 Univariate analysis of biological variables on
overall survival
Biological parameters N OS ( months) HR p
Leucocytes
≥10 000/mm3 23 5.2 2.23 0.0031
<10 000/mm3 30 12.6 CI 95% 1.02-4.15
Neutrophils
< 8000/mm3 38 12.6 3.08 0.0001
≥ 8000/mm3 15 4 CI 95% 1.36-7
Lymphocytopenia
Yes 26 7.6 1.53 0.11- NS
No 27 15.6 CI 95% 0.87-2.7
Hemoglobin
<11 g/dl 9 6.5 0.39 0.0066
≥ 11 g/dl 44 11 CI 95% 0.14-1.09
Albuminemia
≥ 35 g/L 32 14.5 0.27 0.0001
<35 g/L 10 5.22 CI 95% 0.09-0.84
Alkaline phosphatases
< 100 UI/L 20 11.2 1.93 0.0165
≥ 100 UI /L 35 6.4 CI 95% 1.12-3.32
Corrected calcemia
≥ 2,60 mmol/L 11 5 2.38 0.008
< 2,60 mmol/L 38 11.2 CI 95% 0.96-5.88
C-Reactive Protein < 0.0001
≥ 7 mg/L 35 6.45 4.3
< 7 mg/L 11 34 CI 95% 2.38-7.8
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fracture (1 pt), treated by osteosynthesis and
adjuvant radiotherapy (30 Gy/10 fr)
– T7 spine metastasis was treated by radiotherapy
(1 pt) followed by laminectomy due to spinal
chord compression. L3 metastasis in one
patient without neurologic impairment
was treated by exclusive radiotherapy 30
Gy/10 fr.
– Osteolytic metastasis located on scapula or coracoid
apophysa (3 pts) were treated by exclusive
radiotherapy (30 Gy/10 fr).ble 5 Multivariate analysis of clinical and biological
arameters on overall survival
HR p
-1 vs T 2-3-4 2.8 0.004
eight loss > 10% 3.1 0.02
F-1 status 2.42 0.004
inal epidural metastasis 2.5 0.0036
Reactive protein 4.3 0.002– One patient with a biopsy-proven of a sole bone
metastasis of the 4th rib received also exclusive
radiotherapy.
In this subgroup, two non-smoker female patients
were long survivors at 5 years from the diagnosis. Both
of these patients had received a locoregional therapy
with lobectomy on the primary lung cancer, and had been
treated in a curative intent on their bone metastasis, lo-
cated on distal extremities (humeral glene and femoral
bone). Adjuvant radiotherapy was performed in both case.
No relapse occurred in the primary bone site, underlying
the fact that a durable bone response can be obtained with
a multimodal approach.
Discussion
Inaugural SRE in NSCLC patients remains of pejora-
tive prognosis, with a median survival of 8.5 months
and mean survival of 13.4 months. Our study indicate
that locally advanced thoracic T-stage, weight loss >
10%, elevated C-reactive protein at diagnosis, and
TTF-1 status are independent prognosis factors for
survival.
If absence of visceral spreading, and/or solitary bone
metastasis appear to be variables associated with longer
survival respectively of 12.6 and 14.2 months in univariate
analysis, these trend is not meaningful in multivariate
analysis.
To our knowledge, one study have focused on skeletal
metastases as the primary symptom revealing lung
cancer [9], reporting an incidence of bone metastases
revealing lung cancer of 2.4% on a population of 1062 pa-
tients treated between 1976 and 2001, while we report an
incidence of 4.5%. Adenocarcinoma is the first histologic
subtype represented in our serie, accounting for 78% of
our patients. Kagohashi in 2003 reported an adenocarcin-
oma rate of 67% on 24 patients with revealing bone
metastasis [9].
Incidence of adenocarcinoma is rising on the lasts
epidemiologic reports -accounting for more than 45%
of the newly diagnosed cases - and has become the first
histology in women, independently of the smoking sta-
tus [10,11]. It has a tropism for bone dissemination:
metastatic spreading in lung cancer differs according
to histologic subtype and 45% of patients having adeno-
carcinoma are metastatic to bone [12]. Interestingly, most
of our patients present small primary tumor (Tx-T1-T2
accounts for 71% of patients), with node involvement
cN0-N1 showing that bone metastases are more related
to early spreading in the bone than to primary tumour
volume.
Revealing bone site is mainly located on axial skel-
eton (70%). Our findings are comparable to previous
observations, where 70% of symptomatic lesions are
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and only 10% in the cervical spine [13,14].
Our reported cumulative survival rates at 6 months, 1
and 2 years are very closed to those reported by Sugiura
[5] assessing prognostic factors in a serie of 118 patients
with bone metastases from lung cancer (59.9% at
6 months, 31.6% at 1 year, and 11.3% at 2 years) and a
median survival of 7.2 months.
It has been described how the incidence of SRE in the
disease course of NSCLC patients strongly affects survival.
In a study of Tsuya et al. [14] on 135 patients with stage
IV NSCLC, median survival for the patients experiment-
ing a SRE was 6 months versus 1 year, although not sig-
nificant, and median survival after SRE was 4.5 months. In
the medico-economic study by Delea [15] conducted on
534 patients of whom 55% had experienced a SRE, median
survival after the first SRE was 4.1 months.
In surgical series focusing on skeletal metastases in
lung cancer, Weiss et al. report a median survival time
after surgery of 3 months, and a cumulative 12-months
survival after surgery of 13% [7]. Nathan et al. found that
in patients with various histologic types of bone metasta-
ses, lung cancer patients had the shortest median survival
time of 4 months [8]. These surgical series illustrate the
major difficulty in selecting NSCLC patients who are likely
to benefit from heavy surgical procedures. In attempting
to accurately assess the survival expectancy of bone
metastatatic patients, orthopaedic surgeons have estab-
lished a scoring system for the preoperative evaluation
of skeletal metastasis [16,17]. Katagiri et al. reported
five prognostic factors discriminant for survival, namely,
site of primary lesion, performans status, presence of
visceral or cerebral metastasis and multiple skeletal metas-
tases [16]. Forsberg has recently developed and validated
BETS models (Bayesan Estimated Tools for Survival at
3 months and 12-months) including data such as
hemoglobin concentration, preoperative absolute lympho-
cyte count, ECOG performans status, presence of a
complete pathologic fracture, number of bone metastases
and primary oncologic diagnosis [17].
Regarding surgical outcomes, we showed that inaugural
spinal epidural metastasis (SEM) strongly impact outcome,
with a median survival of 3 months for the nine patients
who suffered from SEM, as Schiff et al. who reported a
median survival of 2.75 months after laminectomy for
inaugural SEM [18].
We also confirmed some biological parameters already
known to be predictive of pejorative survival, such as
hemoglobin rate, neutrophil and white blood cell count
[19,20], whereas lymphocytopenia was not statistically
significant. Moreover, we found that pretherapeutic C-
reactive protein level below 7 mg/L was strongly corre-
lated with survival in multivariate analysis. In a study
conducted by Wilop on 210 patients with NSCLC stageIV, evolution of CRP allowed to identify two subgroups of
patients with significant differences in survival (18,8 vs
7,5 months) [21].
Another relevant histological marker is the thyroid
transcription factor-1 (TTF-1). The meta-analysis by
Berghmans et al. showed that TTF-1 positivity was as-
sociated with a statistically significant longer survival
in NSCLC: combined HR of eight studies was 0,64 and
0.53 in the adenocarcinoma subgroup [22]. We also
found this impact of TTF-1 positivity both in univariate
and multivariate analysis, with a MS of 15.4 months versus
6.45 months for negative TTF-1 patients (HR = 0.54), and
believe that TTF-1 status is a reliable marker for survival.
Hypercalcemia is also a well-known adverse pronostic
factor confirmed by our univariate analysis: median
survival is 11.2 months vs 5 months for hypercalcemic
patients (HR = 2.38; CI95% 0.96-5.88, p ≤ 0.008). In ad-
vanced stage, reported rates of hypercalcemia are of
12,5-35% [23], and 22% in the present study.
Indeed, if none of our patients experimented inaugural
malignant hypercalcemia, preventing hypercalcemia dur-
ing the disease course and incidence of second SRE is a
major concern in this population.
Despite their inaugural revealing SRE, only 60% of our
patients received biphosphonates. In previous phase III
study, Rosen et al. demonstrated the long-term efficacy
of zoledronic acid in preventing SRE in patients bearing
skeletal metastasis [24]. Moreover, Hirsh et al. suggested
that patients who had already experienced a SRE were at
higher risk for subsequent SREs than patients with skeletal
involvement without SRE. This over-risk was based on the
SRE history of patients from Rosen’s phase III study evalu-
ating zoledronic acid where this biphosphonate reduced
the risk of SREs by 31%, prolonging the median time to
first SRE by nearly 4 months [25]. In our study, 37% of the
patients experienced a second SRE. Bae et al. reported a
very closed rate of 33% second SRE in the population of
86 patients with first inaugural SRE [6] and a prescription
rate of biphosphonates of 4.5%.
Administration of biphosphonates is here associated
with an increased survival in univariate analysis- but not
in multivariate analysis- with a median survival of 15.4
versus 5.2 months (HR = 0.4, CI95% 0.2-0.79; p = 0.001).
Previous studies already showed a survival advantage of
nearly 6 months for patients who had been treated with
biphosphonates [26,27].
More recently, Denosumab, a human monoclonal anti-
body against RANKL, confirmed its superiority over zole-
dronid acid giving an overall survival improvement in a
population of 811 NSCLC patients with bone metastases
[28,29]. In conclusion, biphosphonates or denosumab
should be early administrated in the course of the disease
for these patients who were shown to be at higher risk of
developing subsequent skeletal-related-event.
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inaugural SRE remains poor, respectively seven and two of
the 55 patients ( 12,7% and 3.6%) are alive at 2 and 5 years.
Case reports of long NSCLC survivors at 5 years with sole
bone metastasis were reported with bone locations on dis-
tal extremities [30]. Bae et al. reported that patients with
single bone metastasis had a survival 2.4 times longer than
others [6].
A study by Okamoto [31] analysing predictive factor
of long survival in stage IV non small cell lung cancer,
found that multimodal treatment including a locoregio-
nal treatment like surgery, and early nodal status were
significantly associated with longer survival. A long term
improvement survival at 5 years can be achieved for pa-
tients after surgical resection of solitary metastases in
brain or adrenal gland of non-small cell lung cancer [32].
We believe that an accurate early staging by PET-TDM
and full body RMN may allow to better select oligometa-
static patients in order to shift them to more aggressive
therapy. Selected patients with single bone metastasis
could benefit from a combination of surgical lung resec-
tion on the primitive tumor and intensified treatment on
the skeletal metastasis, such as surgery and/or hypofrac-
tionated stereotactic body radiation therapy with dose
escalation in a curative intent [33,34].
Limitations
The major limitation of our study included the lack of
recording of EGFR status, at this period of time (2003–
2009). Our population may be heterogeneous regarding
EGFR status, a known-predictive factor for OS and PFS
[5,6]. Only two patients received EGFR TKI as first-line
treatment, nowadays prescribed in EGFR-mutated pa-
tients. However, in the subgroup of twelve patients who
received EGFR TKI as second or third line, median sur-
vival was 18 months, 2.5 times superior than for other
treatment subgroups. Finally, there was a wide range of
chemotherapy regimens and a selection bias of chemo-
therapy use, since 92% of our patients were selected
through a chemotherapy registry.
Conclusion
Despite its shortscomings, this retrospective study rep-
resents one of the largest follow-up of patients with an
inaugural SRE revealing non-small lung cancer. Few
patients with single bone metastasis and no visceral
dissemination were able to achieve survival up to 5 years.
In multivariate analysis, variables significantly associated
with shorter overall survival are locally advanced T stage,
weight loss ≥ 10%, inaugural spinal epidural metastasis,
elevated C-reactive protein and negative TTF-1 status.
Thus, a better selection of oligometastatic NSCLC patients
likely to require or benefit from surgical procedure on
inaugural skeletal metastasis can be made.Abbreviations
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